NCT07278557RecruitingPhase 2
Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia
Assessment of Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia Following Radiotherapy for Oropharynx Cancer
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
Radiation-induced xerostomia (dry mouth) is one of the most common and severe side effects for patients receiving radiation therapy for head and neck cancer. New approaches are needed to reduce this side effect and improve patients' quality of life after treatment. This is a Phase II, single-center, double-masked, parallel-arm, randomized controlled trial. It compares MRI-guided parotid ductal sparing to the standard approach of mean parotid gland sparing, focusing on patient-reported dry mouth outcomes in individuals receiving definitive radiotherapy for oropharyngeal cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- First submitted
- 3 Dec 2025
- Start date
- 28 Jan 2026
- Primary completion date
- Feb 2030
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Diseases
- Head and neck cancer
- NCT number
- NCT07278557
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 98
- From 28 Jan 2026 to the primary completion date, Feb 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior lifetime history of radiation therapy to the head and neck
Other illness
- Patients with Sjogren's disease or baseline xerostomia.
- Patients with an allergy to lemon juice
Other
- An individual who meets any of the following criteria will be excluded from participation
- In this study:
- Patients with lesions involving the salivary glands on diagnostic imaging
- Current pregnancy or lactation.
Who the study is looking for
- To participate in this study a subject must meet all of the eligibility criteria outlined below. Eligibility must be maintained for the subject to be considered eligible for ongoing trial participation.
- Provide written informed consent to participate in the study and HIPAA authorization for release of personal health information.
- Able to comply with study procedures based on the judgment of the clinical investigator.
- Male or female, aged ≥ 18 years at the time of consent.
- Eastern Cooperative Oncology Group performance status 0-2 at the time of consent.
- Women of reproductive potential must use highly effective contraception.
- T0-4, N0-3, M0 stage cancer of the oropharynx (American Joint Committee on Cancer Staging System 8th edition) planned for definitive radiotherapy +/- chemotherapy.
- No contraindications for magnetic resonance imaging (MRI).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of North Carolina at Chapel Hill, Department of Radiation Oncology Coordinator of this site? Confirm its status | Chapel Hill | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.